CAR T-cell therapy for hard-to-treat autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these autoimmune diseases: lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or a type of vasculitis (ANCA-associated).
- Your disease must be active (moderate to severe) based on specific scoring systems used by your doctor.
- You cannot have had CAR T-cell therapy before.
- You must have adequate organ function (heart, liver, kidneys, lungs, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.